IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression-Reference-Cited by-同舟云学术

IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression

Published:2017-01-31 Issue:2 Volume:6 Page:e1181237
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Ohmatsu Hanako¹,Humme Daniel²,Gonzalez Juana³,Gulati Nicholas¹,Möbs Markus²,Sterry Wolfram²,Krueger James G.¹

Affiliation:

1. Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA

2. Department of Dermatology and Allergy, Skin Cancer Center Charité, Charité- Universitätsmedizin Berlin, Berlin, Germany

3. Rockefeller University Center for Clinical and Translational Science, New York, NY, USA

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2016.1181237

Reference59 articles.

1. Evolving Insights in the Pathogenesis and Therapy of Cutaneous T-cell lymphoma (Mycosis Fungoides and Sezary Syndrome)

2. Changing Incidence Trends of Cutaneous T-Cell Lymphoma

3. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States

4. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome

5. Association of the numbers of CD163+ cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pan-cancer analysis reveals IL32 is a potential prognostic and immunotherapeutic biomarker in cancer;Scientific Reports;2024-04-07

2. IL-32 producing CD8⁺memory T cells and Tregs define the IDO1 / PD-L1 niche in human cutaneous leishmaniasis skin lesions;2024-01-03

3. IL-32 as a potential biomarker and therapeutic target in skin inflammation;Frontiers in Immunology;2023-09-01

4. Celastrol acts as a new histone deacetylase inhibitor to inhibit colorectal cancer cell growth via regulating macrophage polarity;Cell Biology International;2022-11

5. Immunometabolism in the Bladder Cancer Microenvironment;Endocrine, Metabolic & Immune Disorders - Drug Targets;2022-10